Medghoul Lamia, Grosjean Julien, Marguet Christophe, Petat Hortense
Department of Medical Pediatrics, Centre Hospitalier Universitaire de Rouen, Rouen, France.
Departement of Digital Health, Centre Hospitalier Universitaire de Rouen & LIMICS UMR 1142, Sorbonne Université & Sorbonne Paris Nord, Rouen, France.
Clin Exp Pediatr. 2025 Jul;68(7):497-502. doi: 10.3345/cep.2025.00122. Epub 2025 Apr 1.
Postinfectious bronchiolitis obliterans (PIBO) is a rare chronic obstructive pulmonary disease that occurs after a respiratory infection. Its diagnosis is generally based on clinical history, respiratory symptoms, and computed tomography (CT) findings.
Here we evaluated the frequency of exacerbations, clinical progress, and inhaled corticosteroid (ICS) usage in children diagnosed with PIBO with or without comorbid bronchopulmonary dysplasia (BPD).
This retrospective observational study was conducted in Rouen, France. The inclusion criteria were as follows: child diagnosed with PIBO (history of respiratory infection, airway obstruction with no or poor response to bronchodilation treatment, and/or mosaic pattern or trapping on chest high-resolution CT) in 2009-2024 treated with intravenous corticosteroid pulses.
Fifty-seven patients were included: 13 (23%) with BPD and 44 (77%) without BPD. The mean age at diagnosis was 7.0±3.6 months, with no significant intergroup difference. We observed a significant reduction in exacerbations following corticosteroid pulse treatment as soon as 6 months (P<0.001), with persistent effects observed up to 24 months (P=0.02). We also noted a reduced daily ICS dose starting at 12 months (P=0.03). Respiratory syncytial virus is the most commonly identified causative virus, followed by rhinoviruses and adenoviruses. The viral codetection rates were 18% and 61% in the BPD and non-BPD groups, respectively.
In our cohort, intravenous corticosteroid pulse treatment effectively treated PIBO, with a rapid and long-lasting reduction in exacerbations and ICS requirements. BPD was a significant comorbidity of PIBO.
感染后闭塞性细支气管炎(PIBO)是一种罕见的慢性阻塞性肺疾病,发生于呼吸道感染后。其诊断通常基于临床病史、呼吸道症状和计算机断层扫描(CT)结果。
在此,我们评估了合并或不合并支气管肺发育不良(BPD)的PIBO患儿的病情加重频率、临床进展和吸入性糖皮质激素(ICS)的使用情况。
这项回顾性观察研究在法国鲁昂进行。纳入标准如下:2009年至2024年期间诊断为PIBO(有呼吸道感染病史、气道阻塞且对支气管扩张治疗无反应或反应不佳,和/或胸部高分辨率CT显示马赛克样改变或气体潴留)并接受静脉糖皮质激素冲击治疗的儿童。
共纳入57例患者:13例(23%)合并BPD,44例(77%)不合并BPD。诊断时的平均年龄为7.0±3.6个月,组间无显著差异。我们观察到糖皮质激素冲击治疗后6个月病情加重情况即有显著减少(P<0.001),直至24个月仍有持续效果(P=0.02)。我们还注意到从12个月开始每日ICS剂量减少(P=0.03)。呼吸道合胞病毒是最常见的致病病毒,其次是鼻病毒和腺病毒。BPD组和非BPD组的病毒共检测率分别为18%和61%。
在我们的队列中,静脉糖皮质激素冲击治疗有效治疗了PIBO,病情加重和ICS需求迅速且持久地减少。BPD是PIBO的一种重要合并症。